In contrast, in a clinical trial, 11 patients with R/R cancers did not experience CRS or neurotoxicity when treated with HLA–mismatched anti‐CD19 CAR‐NK cells derived from cord blood [3]. The gene discussed is CD19; the disease is cancer.